<DOC>
	<DOCNO>NCT00905034</DOCNO>
	<brief_summary>This goal clinical research study learn combination methotrexate , pegylated-L-asparaginase , vincristine , dexamethasone ( also rituximab patient ) help control ALL respond previous treatment come back response chronic myeloid leukemia ( CML ) .</brief_summary>
	<brief_title>Methotrexate , Vincristine , Pegylated L-Asparaginase Dexamethasone ( MOAD ) Acute Lymphoblastic Leukemia ( ALL ) Salvage</brief_title>
	<detailed_description>The Study Drugs : Methotrexate design disrupt cell make repair DNA ( genetic material cell ) `` copy '' . Vincristine design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die . Pegylated-L-asparaginase design get rid important building block protein leukemia cell . Dexamethasone steroid cause leukemia cell breakdown . Rituximab design attach lymphoma cell , may cause die . Study Drug Administration : If find eligible take part study , receive methotrexate needle vein Days 1 15 ( +/- 2 day ) 2 hour . You receive vincristine vein Days 1 , 8 15 ( +/- 2 day ) 30 minute . You receive pegylated-L-asparaginase vein Days 2 16 ( +/- 2 day ) 2 hour . You receive dexamethasone vein 30 minute mouth Days 1-4 15-18 ( +/- 2 day ) . If leukemia cell protein call cluster differentiation antigen 20 ( CD20 ) , also receive rituximab vein Days 1 15 Cycles 1-4 ( +/- 2 day ) 2-8 hour . Each cycle least 28 day . If Philadelphia positive ALL , may continue receive tyrosine kinase inhibitor ( TKI ) . Examples TKIs include Imatinib , Dasatinib , Nilotinib . If take TKI , may begin take TKI . Your doctor describe treatment TKIs detail . Once blood count improve leukemia control doctor may decide continue treatment every 4-6 week . If leukemia control first cycle , doctor may decide start next cycle without blood count improve . Study Visits : During Cycle 1 , blood ( 2 teaspoon ) draw least 1 time week routine test . If doctor think necessary , may ask additional blood drawn . Between Days 14-28 Cycle 1 , bone marrow aspirate check status disease . This test may delay repeat doctor think remission . Since pegylated-L-asparaginase cause problem blood clot inflammation pancreas , Days 2 16 All cycle , blood ( 2 teaspoon ) drawn check well blood clot check health pancreas . During Cycles 2- 6 , blood ( 2 teaspoon ) draw routine test least 2 time month . If doctor think necessary , may bone marrow aspirate check status disease . Length Study : You may receive study drug 6 cycle . You take study early disease get bad , experience intolerable side effect , doctor think longer best interest receive study drug ( ) . This investigational study . Methotrexate , pegylated-L-asparaginase , vincristine FDA approve use ALL . Dexamethasone FDA approve steroid steroid traditionally important part treatment leukemia . Rituximab FDA approve treatment non-Hodgkin 's lymphoma . The combination drug investigational . Up 60 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Previously treat ALL ( include Burkitt 's lymphoma ) lymphoblastic lymphoma relapse primary refractory ; without viable stem cell transplant option . Patients previously treat Philadelphia chromosome positive ALL also eligible ; 2 . Chronic myeloid leukemia blast phase 3 . Zubrod performance status &lt; /= 3 ; 4 . Adequate liver function ( bilirubin &lt; /= 3.0mg/dl , unless consider due tumor ) , renal function ( creatinine &lt; /= 3.0 mg/dl unless consider due tumor ; 5 . Age &gt; /= 1 year 6 . Understand voluntarily sign informed consent form . 7 . For pediatric patient ( age &gt; /= 1 year &lt; /= 18 year ) , Lansky performance status &gt; /=50 8 . For pediatric patient ( age &gt; /= 1 year &lt; /= 18 year ) , second great relapse 1 . Pregnant patient 2 . Prior history allergic reaction , serious pancreatitis , hemorrhagic thrombotic event PEGlasparaginase component .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Vincristine</keyword>
	<keyword>PEG-l-asparaginase</keyword>
	<keyword>PEG asparaginase</keyword>
	<keyword>Pegaspargase</keyword>
	<keyword>Oncaspar</keyword>
	<keyword>Polyethylene Glycol Conjugated Lasparaginase-H</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
</DOC>